CIK 0001659323
ITRM Iterum Therapeutics plc
Insider trading from SEC Form 4. Last filing Nov 20, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
3
with a Form 4 at this company
Signals
Open-market buys and sells at Iterum Therapeutics plc, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Michael W. Dunne director buy | $2,191 6,000 shares | +3% | - | |
| 18Weak | Michael W. Dunne director buy | $11k 15,000 shares | +7% | - |
Transactions
The last 5 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 18, 2025 | Michael W. Dunne director | POpen-market purchase Ordinary Shares | +6,000 | $0.37 | $2,191 | 241,001 | Nov 20, 2025 |
| Aug 8, 2025 | Michael W. Dunne director | POpen-market purchase Ordinary Shares | +15,000 | $0.72 | $11k | 235,001 | Aug 12, 2025 |
| Jul 1, 2025 | Christine Coyne Chief Commercial Officer | AGrant or award Share Option (Right to Buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Jul 3, 2025 |
| Jan 13, 2025 | Ronald Hunt director | JOther 6.500% Exchangeable Senior Subordinated Note due 2025derivativeindirect: By New Leaf Ventures III, L.P. | - | $2,208,000.00 | - | - | Jan 23, 2025 |
| Jan 13, 2025 | Ronald Hunt director | JOther 6.500% Exchangeable Senior Subordinated Note due 2025derivativeindirect: By New Leaf Biopharma Opportunities II, L.P. | - | $792,000.00 | - | - | Jan 23, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Christine CoyneChief Commercial Officer
- Michael W. Dunnedirector
- Ronald Huntdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.